<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of systemic therapies for metastatic castration-resistant prostate cancer (CRPC)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of systemic therapies for metastatic castration-resistant prostate cancer (CRPC)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Overview of systemic therapies for metastatic castration-resistant prostate cancer (CRPC)</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="12%"></colgroup> <colgroup width="16%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Approach</td> <td class="subtitle1">Indications</td> <td class="subtitle1">Route,<br/> schedule</td> <td class="subtitle1">Steroids</td> <td class="subtitle1">Symptoms,<br/> disease burden</td> <td class="subtitle1">Contraindications</td> <td class="subtitle1">PSA response to treatment</td> <td class="subtitle1">Median overall survival benefit for males with advanced disease*</td> </tr> <tr class="divider_bottom"> <td>Abiraterone</td> <td>Metastatic CRPC</td> <td>Oral, daily</td> <td>Required</td> <td>–</td> <td>Severe liver dysfunction, hypokalemia, heart failure</td> <td>Yes</td> <td> <p>Post-docetaxel: 4.6 months<sup>[1]</sup> compared with prednisone alone (HR for death 0.53, 95% CI 0.45-0.62)</p> Chemotherapy naïve: 4.4 months<sup>[2]</sup> compared with prednisone alone (HR for death 0.81, 95% CI 0.70-0.93) </td> </tr> <tr class="divider_bottom"> <td>Enzalutamide</td> <td>Metastatic CRPC</td> <td>Oral, daily</td> <td>Not required</td> <td>–</td> <td>Seizures</td> <td>Yes</td> <td>4.8 months<sup>[3]</sup></td> </tr> <tr class="divider_bottom"> <td>Sipuleucel-T</td> <td>Metastatic CRPC, pre- or post-docetaxel</td> <td>IV, every 2 weeks for 3 doses</td> <td>Possibly contraindicated</td> <td>Asymptomatic or minimally symptomatic</td> <td>Steroids, opioids for cancer-related pain, GM-CSF, liver metastases, rapidly progressive disease</td> <td>No</td> <td>4.1 months<sup>[4]</sup></td> </tr> <tr class="divider_bottom"> <td>Docetaxel</td> <td>Metastatic CRPC</td> <td>IV, every 3 weeks</td> <td>Required</td> <td>–</td> <td>Moderate liver dysfunction, cytopenias</td> <td>Yes</td> <td>2.5 months<sup>[5]</sup></td> </tr> <tr class="divider_bottom"> <td>Cabazitaxel</td> <td>Post-docetaxel, metastatic CRPC</td> <td>IV, every 3 weeks</td> <td>Required</td> <td>–</td> <td>Moderate liver dysfunction, cytopenias</td> <td>Yes</td> <td>2.4 months<sup>[6]</sup> compared with mitoxantrone/prednisone (HR for death 0.70, 95% CI 0.64-0.86)</td> </tr> <tr class="divider_bottom"> <td>Radium-223</td> <td>Symptomatic bone metastases with no known visceral metastases</td> <td>IV, every 4 weeks</td> <td>Not required</td> <td>Symptomatic bone metastases</td> <td>Visceral metastases</td> <td>Not reported</td> <td>3.6 months<sup>[7]</sup></td> </tr> <tr> <td>Lutetium Lu-177 vipivotide tetraxetan</td> <td>Metastatic PSMA-expressing CRPC</td> <td>IV, every 6 weeks</td> <td>Not required</td> <td>–</td> <td>None</td> <td>Yes</td> <td>4 months compared with glucocorticoids or androgen signaling inhibitors<sup>[8]</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>CRPC: castration-resistant prostate cancer; PSA: prostate-specific antigen; HR: hazard ratio; IV: intravenous; GM-CSF: granulocyte-macrophage colony-stimulating factor; PSMA: prostate-specific membrane antigen.</p>
* Docetaxel is also indicated for castration-sensitive disease in combination with androgen deprivation therapy for metastatic prostate cancer.</div><div class="graphic_reference">References:
<ol>
<li>Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983.</li>
<li>Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16:152.</li>
<li>Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187.</li>
<li>Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411.</li>
<li>Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242.</li>
<li>de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376:1147.</li>
<li>Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213.</li>
<li>Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385:1091.</li>
</ol></div><div id="graphicVersion">Graphic 127197 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
